B37.8 Candidiasis of other sites

Name of the Condition

• Candidiasis of Other Sites (ICD Code: B37.8)
• Technical term: Candidiasis of other sites
• ICD-10 Code: B37.8

Summary

Candidiasis of other sites is a fungal infection caused by Candida species, affecting body areas not classified under more specific Candidiasis subtypes. It occurs when Candida, a normally present yeast, overgrows in localized or systemic sites, leading to inflammation and tissue involvement. The condition may present as superficial or invasive, depending on the site and host factors.

Causes

Candidiasis of other sites results from the overgrowth of Candida fungi, which are part of the normal microbial flora. This overgrowth can be triggered by disruptions to the body's natural balance, such as antibiotic use, hormonal changes, or weakened immune function. Invasive forms may arise from hematogenous spread or direct inoculation into non-mucosal sites.

Risk Factors

• Weakened immune system (e.g., HIV/AIDS, chemotherapy, immunosuppressive therapy).
• Prolonged use of broad-spectrum antibiotics or corticosteroids.
• Diabetes mellitus or poorly controlled blood sugar.
• Invasive medical procedures or indwelling devices.
• Chronic skin conditions or moisture-related skin breakdown.
• Malnutrition or systemic illness.

Symptoms

• Localized redness, swelling, or discharge at the affected site.
• Pain, itching, or discomfort in the involved area.
• Ulceration or tissue breakdown (invasive cases).
• Systemic symptoms (e.g., fever, fatigue) if infection spreads.

Diagnosis

Diagnosis involves a physical examination and targeted testing, such as cultures, microscopy, or histopathology of the affected site. Laboratory confirmation of Candida species and assessment of tissue invasion are key. Imaging may be used for deep or systemic involvement to evaluate extent and guide treatment.

Treatment Options

Treatment depends on the site, severity, and host factors. Topical antifungals (e.g., creams, powders) are used for superficial infections. Oral or intravenous antifungals (e.g., fluconazole, echinocandins) are employed for invasive or widespread cases. Underlying risk factors, such as immune suppression, must be addressed to prevent recurrence.

Prognosis and Follow-Up

Prognosis varies by site and host health. Superficial infections typically resolve with treatment, while invasive cases may require prolonged therapy. Follow-up includes monitoring for recurrence, especially in immunocompromised patients, and adjusting treatment for persistent or worsening symptoms.

Complications

• Chronic or recurrent infection.
• Tissue damage or scarring at the affected site.
• Systemic spread (e.g., candidemia) in severe cases.
• Resistance to antifungal therapy with prolonged use.

Lifestyle & Prevention

• Maintain good hygiene and keep skin dry to reduce moisture-related risk.
• Manage underlying conditions like diabetes or immune disorders.
• Avoid unnecessary antibiotic use to preserve microbial balance.
• Use protective measures during invasive procedures if at risk.

When to Seek Professional Help

Seek care if symptoms persist, worsen, or involve systemic signs (e.g., fever, fatigue). Prompt evaluation is critical for invasive or recurrent cases, particularly in immunocompromised individuals, to prevent complications.

Tips for Medical Coders

Document the specific site of infection (e.g., skin, eye, bone) and any associated risk factors (e.g., immunosuppression) to support code assignment. Ensure clinical correlation with laboratory or imaging findings to confirm Candida involvement. Code B37.8 is appropriate when the site is not specified by a more detailed subcategory.